dataesr/scientific-paragraphs-categorization huggingface dataset:
gov/search?id=%22NCT00798213%22 https://clinicaltrials. gov/search?id=%22NCT00036855%22 https://clinicaltrials. gov/search?id=%22NCT04754945%22 https://clinicaltrials. gov/search?id=%22NCT02219256%22 https://clinicaltrials. gov/search?id=%22NCT03864185%22 CHEMBL1201506 CHEMBL1201606 CHEMBL2109348 CHEMBL4297789 CHEMBL1201576 GEMTUZUMAB OZOGAMICIN IBRITUMOMAB TIUXETAN LFB-R603 MT-3724 RITUXIMAB Antibody Myeloid cell surface antigen CD33 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Unknown B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Binding agent Binding agent Binding agent Binding agent Binding agent EFO_0000224 EFO_0000565 EFO_0000095 EFO_0005952 EFO_1001050 acute promyelocytic leukemia leukemia chronic lymphocytic leukemia non-Hodgkins lymphoma multiple system atrophy 2 Withdrawn 1 Completed 1 Completed 2 Terminated 2 Recruiting https://clinicaltrials.
gov/search?id=%22NCT01548911%22 https://clinicaltrials. gov/search?id=%22NCT00048737%22 https://clinicaltrials. gov/search?id=%22NCT01098188%22 https://clinicaltrials. gov/search?id=%22NCT03645395%22 https://clinicaltrials. gov/search?id=%22NCT04004819%22 CHEMBL1201506 CHEMBL1201606 CHEMBL2109150 CHEMBL4297789 CHEMBL1201576 GEMTUZUMAB OZOGAMICIN IBRITUMOMAB TIUXETAN LINTUZUMAB MT-3724 RITUXIMAB Antibody Myeloid cell surface antigen CD33 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody Myeloid cell surface antigen CD33 other Unknown B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Binding agent Binding agent Other Binding agent Binding agent EFO_0000095 EFO_0000574 MONDO_0001475 EFO_0000095 EFO_1001264 chronic lymphocytic leukemia lymphoma neutropenia chronic lymphocytic leukemia Anemia, Hemolytic, Autoimmune 1 Completed 1 Terminated 2 Completed 1 Active, not recruiting 2 Completed https://clinicaltrials.
gov/search?id=%22NCT00038831%22 https://clinicaltrials. gov/search?id=%22NCT00372905%22 https://clinicaltrials. gov/search?id=%22NCT00002800%22 https://clinicaltrials. gov/search?id=%22NCT02361346%22 https://clinicaltrials. gov/search?id=%22NCT00749112%22,https://clinicaltrials. gov/search?id=%22N CHEMBL1201506 CHEMBL1201606 CHEMBL2109150 CHEMBL4297789 CHEMBL1201576 GEMTUZUMAB OZOGAMICIN IBRITUMOMAB TIUXETAN LINTUZUMAB MT-3724 RITUXIMAB Antibody Myeloid cell surface antigen CD33 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody Myeloid cell surface antigen CD33 other Unknown B-lymphocyte antigen CD20 binding agent Antibody B-lymphocyte antigen CD20 binding agent Binding agent Binding agent Other Binding agent Binding agent EFO_0000198 EFO_0001378 EFO_0000198 EFO_0000403 EFO_1001946 myelodysplastic syndrome multiple myeloma myelodysplastic syndrome diffuse large B-cell lymphoma childhood B acute lymphoblastic leukemia 1 Active, not recruiting 1 Completed 1 Completed 1 Active, not recruiting 2 Terminated https://clinicaltrials.
gov/search?id=%22NCT01020539%22 https://clinicaltrials. gov/search?id=%22NCT00477815%22 https://clinicaltrials. gov/search?id=%22NCT00502112%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT02361346%22 https://clinicaltrials. gov/search?id=%22NCT00058461%22.
Those who agreed to participate completed a standard questionnaire while waiting for their appointment. A total of 2198 adult hypertensive patients were enrolled during outpatient consultations, in the cardiology departments of the participating hospitals. The first section of the questionnaire was completed by patients and collected data on demographic factors and medication details including self-reported adherence. The second section was completed by the physician during the consultation and provided data on patient socioeconomic status, treatment prescribed, BP values, complications and cardiovascular risk factors.
22 The scale scores from 0 to 8: high adherence was defined as a score of 8, and poor adherence as a score <8. An additional item on the impact of patient financial situation on adherence was included with a yes/no answer: 'Some medications are expensive. Did you ever skip taking your treatment for financial reasons?'. The country income was obtained from the World Bank database (http://data. worldbank. org/country) and categorised into low-income and middle-income countries. Individual patient wealth categories were assessed by the physician and classified as low (patients who have difficulties to afford medical consultations), middle (patients who can manage paying medical consultations) and high (no difficulties to pay medical consultations). Complications of hypertension were assessed in the physician questionnaire by the question 'If the patient has hypertension, has he/she presented with complications?' (yes/no).
RESULTS Out of 2198 patients with hypertension included in the EIGHT study, 2128 participants had data on TM use. Of them, 512 (24%) reported using TM, and this percentage varied drastically across countries from 10% in the Congo to 48% in Guinea (figure  1 , p value for difference <0. 001). Participants characteristics according to use of TM, and unadjusted t-tests and χ 2 are presented in table 1. Those reporting using TM were on average slightly older (59±11 years) than non-users (58±12 years, p value for difference=0. 05), more likely to be male, live in a rural area, to have poor treatment adherence and to report missing treatment because it is too expensive than those not reporting TM use. No striking difference was observed regarding country level income or individual wealth index, time of diagnostic of hypertension, CVD risk factors and lifestyle (table 1, unadjusted t-tests and χ 2 ).
The negative association that we observe is not likely to represent an intrinsic deleterious effect of TM, but rather the use of TM may be a consequence of various factors that led to a worse hypertension profile. Second, our main exposure of interest, use of TM, was assessed with only one self-reported question. It did not include information on exposure duration of TM, whether it was prior or posterior to the diagnostic of hypertension. Moreover, it would have been very useful to have detail on the type of TM (medicinal herbs, potions, prayers, incantations, meditation, other modalities) and on drivers of use of TM such as low cost, greater accessibility, trust and confidence in traditional healers. Moreover, it has been shown that it is common for patients to hide use of TM to their healthcare providers,  4  and we did not have this data available.
Acknowledgements The authors would like to thank the patients and the members of the  African Research Network  for their participation in this research. Contributors XJ is the guarantor of this work. XJ, IBD and MAn designed the study and take responsibility for integrity of the data and accuracy of data on September 9, 2022 by guest. Protected by copyright. http://gh. bmj. com/BMJ Glob Health: first published as 10. 1136/bmjgh-2021-008138 on 2 June 2022. Downloaded from.
The independent clinical research organisation drew up the computerized randomization list, and the patient's randomization number was accessed through a secure site by a site study team member. Randomisation was performed within 2 hours after enrolment. Eligible patients were randomised 1:1 to receive either convalescent plasma or usual care. The latter could include the use of dexamethasone, tocilizumab, supportive care including supplemental oxygen, antivirals, and antibiotics. A Data and Safety Monitoring Board (DSMB) provided guidance to the trial after inclusion of every 60 patients.
Pre-defined subgroups analyses included immunosuppression status (underlying immunodeficiency: yes/no), duration of symptoms before randomization (≤5 days, > 5 days), and use of steroids. Safety data included all clinical and biological adverse events observed during study follow-up. Immunodeficiency was defined as the presence of at least one of the following medical conditions: active malignant neoplasm, lymphoid or myeloid neoplasms, hematopoietic stem cell or solid organ transplantation, or HIV/AIDS not on highly active antiretroviral treatment.
CORIMUNO-CORIPLASM was an embedded multicentric, open-label randomized controlled trial in patients with moderate COVID-19 pneumonia conducted in 14 French hospitals across France (NCT04345991). Ethical clearance was obtained from CPP Ile de France VI on April 10, 2020 (no. 26-20 Med. 1°). The full trial protocol and statistical analysis plan is available in Appendix II and III.
From the 1781 unique records identified from the electronic databases and conference proceedings screened, 49 unique studies represented across 56 publications (53 full-text articles, 3 conference abstracts) were eligible for inclusion. Evidence from these studies suggested that AboBoNT-A dose given per muscle in clinical practice varies considerably, with only a slight trend toward a relationship between dose and muscle volume. Expertbased consensus is needed to inform recommendations for standardizing AboBoNT-A treatment initiation doses based on muscle volume.
Study Selection The literature searches identified 1781 unique records from the electronic databases. Of these, 349 abstracts met the criteria for full-text review, which determined that 53 of the publications were eligible for inclusion in the systematic review. In addition, 3 eligible conference abstracts were identified from the grey literature searches of conference proceed-ings, so resulting in a total of 56 publications (see Figure  1 ). Most of these (49 of 56) were the primary publications for unique studies, with the rest (7 of 56) being deemed related publications because of a clear overlap with population/patient samples reported in some of the primary publications, based on details of the trial/cohort name, and enrollment years.
Risk of Bias The 46 full-text studies included in the systematic review included 23 RCTs, seven quantitative non-randomized studies, and 16 quantitative descriptive studies (Appendix A). The risk-of-bias assessment indicated no concerns regarding study quality across the 23 RCTs, but not all assessment questions could be fully answered for the non-randomized and quantitative descriptive studies. However, these data were not considered to have a material bearing on the findings of the systematic review because the primary focus of the quality-assessment tool was the impact of study quality on treatment outcomes, rather than on assigned treatment dosing (the focus of the review).
Treatment Information Available from Included Studies Studies were selected for inclusion in the systematic review on the basis that they reported a mean/median AboBoNT-A dose, a fixed dose (i. e. , patients received a specific dose for a specific muscle) or a dose range for a specific muscle. Although some studies also included other treatment arms (e. g. , placebo/control or another botulinum toxin A treatment), only data relating to AboBoNT-A were extracted. The data on the administration of AboBoNT-A derived from individual studies for analysis in the systematic review are presented in Appendix B. The range of concomitant treatments used with AboBoNT-A across the studies included other medications, rehabilitation programs (e. g. , physiotherapy and occupational therapy), and electrical stimulation, and one study used robot-assisted gait training to improve patient walking ability  [48].
Information Sources Searches were conducted in MEDLINE, MEDLINE In-Process and Embase via Ovid SP (https://ovidsp. ovid. com, accessed on 12 November 2020). The following conferences were also searched for relevant abstracts from 2018 to 2020 meetings: (1) International Society of Physical and Rehabilitation Medicine (2018: Paris, France; 2019: Kobe, Japan; 2020: virtual); (2) World Congress for Neurorehabilitation (2018: Mumbai, India; 2020: virtual); (3) Toxin's (International Neurotoxin Association; 2019: Copenhagen, Denmark; 2021: virtual). In addition, the bibliographies of relevant systematic reviews published in the past three years and identified during the screening of material retrieved by the searches were cross-checked as a quality-assurance step to identify any relevant studies that were not identified through the electronic database searches.
Selection Process Once the literature searches had been conducted and duplicate records across the databases had been removed, each title and abstract identified was screened by two independent investigators according to the inclusion/exclusion criteria. The full-text articles of studies accepted at the abstract level were retrieved for further review. The full-text screening was conducted by two independent investigators using the same inclusion and exclusion criteria that had been applied during abstract screening. Accepted articles needed to meet all of the inclusion criteria and none of the exclusion criteria. During both rounds of screening, discrepancies were resolved through discussion between investigators, and a third, senior investigator was consulted if necessary.
Data Collection Process Extraction of data from the included studies was performed using a Microsoft Excel ®based data extraction template. The data extraction was conducted by one investigator, and reviewed by a second, senior investigator to ensure consistency and accuracy as a validation step. Any discrepancies were resolved in discussion with a third investigator by comparing the collected data with the information provided by the full paper or abstract. Extracted items included baseline characteristics (population and disease etiology), and information related to treatment with AboBoNT-A (dose and type of value [mean, median, fixed, range], upper and/or lower limb, muscle treated). Patient and treatment characteristics were only extracted for the patient group receiving AboBoNT-A; information on comparator treatments or comparative outcome data were not extracted.
For the COI gene, the reaction mix contained 6 lL of 1/20 template DNA dilution, 2. 5 lL of 10Â reaction buffer, 1. 5 mM MgCl 2 , 0. 2 mM dNTP, 20 pmol of each primer and 1 UI of Taq polymerase (Eurogentec). PCR was conducted at 95 °C for 3 min, followed by 35 cycles at 94 °C for 1 min, 54 °C for 30 s and 72 °C for 1 min with a final extension at 72 °C for 10 min. PCR products were identified by agarose gel electrophoresis stained with Midori green advance (Nippon genetics). All positive PCR products were sent to Eurofins Genomics for Sanger sequencing in both directions. Sequences were aligned with Muscle (http://www. drive5. com/muscle) as implemented in MEGA X (https://www. megasoftware. net/). COI sequences were also directly submitted to Boldsystems (www. barcodeoflife. org) for blast analysis.
aegypti collected worldwide were used as a reference panel (Online material 1. 3). Loci that fail to genotype at 80% or more of the individuals from the global dataset were filtered out from the 22,849 loci obtained from the SNP-chip that met Mendelian expectations, using thegeno 0. 2 option in plink 1. 9 ([6]; www. cog-genomics. org/plink/1. 9/). Subsequently, individuals with more than 5% missing data were removed with themind 0. 05 option. The final dataset had 22,845 SNPs and 784 individuals from across Ae. aegypti distribution (including the individual from Marseille). Genetic assignment tests of the Ae. aegypti from Marseille against the worldwide reference dataset were performed in GeneClass2  [34]. Previous studies have shown higher accuracy of this assignment method using SNPs  [13, 24].
Ten independent runs were conducted with sets of 3500 SNPs drawn at random using the commandthincount 3500 from PLINK 1. 9. (  [6] ; www. cog-genomics. org/ plink/1. 9/), and the Bayesian criteria for likelihood estimation to determine the population-assignment ranking  [36]. Selfassignment tests on the SNP reference dataset resulted in 97. 98 ± 0. 22% of individuals assigned to the expected countries.
Tracking of candidate vessel carriers Information on boats arriving in the port of Marseille from May to July was requested from the port authorities, including widely the period of capture of the Ae. aegypti specimen. Aedes aegypti is not a good flyer  [15] , so we restricted our search to vessels that had docked up to a distance of 1300 m from the place of capture. Consequently, every dock used during the trapping period was plotted on a map and distances from the place of capture calculated using QGIS 2. 18 (Quantum Geographic Information System) software (Fig. 1 ). Due to the unknown variability of the berthing locations, the orientations of the boats along the dock and their large size, we used distance classes to which we assigned coefficients inversely proportional to the distance to the place of capture.
The coefficient and the trapping index formula are presented in Online material 2. The most helpful information, i. e. , countries of origin of the vessels, was absent from the database; only the last stopover was mentioned. To fill this gap, a database of the regular shipping lines was built and analyzed to identify the riskiest lines. Thus, for each shipping line, an import risk index was established according to different parameters: travel time, number of transhipments and presence of Ae. aegypti in the country of origin. The last parameter received different coefficients depending on the presence of the species in the country, according to the following references (  [10, 17, 25] , ECDC mosquitomaps 2019; https://www. ecdc. europa. eu/en/disease-vectors/ surveillance-and-disease-data/mosquito-maps).
The rest of the tests assigned the individual to a population from Burkina Faso (2/10). The arriving vessel database reported 406 dockings and included 138 different boats. Thirty-two local boats (docked 190 times) were excluded. The 216 remaining dockings (107 boats) were assigned a range of trapping indices between 0. 1 and 5 (Online material 2). Among them, the 20 riskiest vessels that docked closest to the place of capture during the trapping period belonged to 5 companies and are shown in Table  2. The regular shipping lines database compiled 196 lines with a range of import risk indices between 0 and 122 (Online material 3). The 10 riskiest shipping lines concerning the same 5 companies and 7 areas are presented in Table  3. The maritime lines linking West Africa and the GPMM are the most represented and one of them links Senegal and the GPMM in a minimum of 6 days.
Supplementary materials The Supplementary materials of this article are available at https://www. parasite-journal. org/10. 1051/parasite/2022043/olm. Online material 1: 1. 1 Map of the eastern dock of the GPMM and mode of shipping according to the docks; 1. Online material 3: Regular maritime lines of the eastern dock of the "Grand Port Maritime de Marseille" (GPMM) in 2018. Contains the database (maritime lines list with the linked ports, the presence of Aedes aegypti in the country linked, the travel time and the occurrence of a transhipment), the risk weighting method applied to each maritime line and the results of this weighting. (Excel file with 3 sheets).
Map of the eastern dock of the GPMM with location of traps and breeding sites; 1. 3. Populations included in the global genetic panel of Ae. aegypti used in the present study; and 1. 4. Photomicrograph of the specimen Aedes (Stegomyia) aegypti (L. ) female collected by the Mosquito Magnet Trap No. 2 in the GPMM between June 29 and July 23, 2018. (PDF file) Online material Maritime traffic of the eastern dock of the Grand Port Maritime of Marseille (GPMM) from May 1 to July 31, 2018. Contains the database (boat list with the docking date and the last port frequented), the risk weighting method applied to each vessel and the results of this weighting. (Excel file with 4 sheets).
Acknowledgements. We would like to thank colleagues all around the world who contribute to building the Ae. aegypti reference database and to  J. R. Powell  for his contribution in generating the global genetic panel of Ae. aegypti. The technical platform dedicated to vectors at IRD is a member of the  Vectopole Sud network  and of the sharing facilities from the  LabEX CEMEB  ( Centre Méditerranéen de l'Environnement et de la Biodiversité ) in Montpellier,.
2. 2 : 22 Map of the eastern dock of the GPMM with location of traps and breeding sites; 1. 3. Populations included in the global genetic panel of Ae. aegypti used in the present study; and 1. 4. Photomicrograph of the specimen Aedes (Stegomyia) aegypti (L. ) female collected by the Mosquito Magnet Trap No. 2 in the GPMM between June 29 and July 23, 2018. (PDF file) Online material Maritime traffic of the eastern dock of the Grand Port Maritime of Marseille (GPMM) from May 1 to July 31, 2018. Contains the database (boat list with the docking date and the last port frequented), the risk weighting method applied to each vessel and the results of this weighting. (Excel file with 4 sheets).
Study participants The study was carried out by the Institut Hospitalo-Universitaire Méditerranée Infection, Assistance Publique-Hôpitaux de Marseille, France, in collaboration with the Department of Periodontology at Aix-Marseille University, Marseille, France. The study was approved by the Comité de Protection des Personnes Sud-Ouest et Outre-Mer 1 (n ID RCB: 2020-A01234-35-CPP 1-20-075 ID9806) as part of the mouth microbiota inventory. The study participants and a negative control participant were recruited from patients presenting to the Institut Hospitalo-Universitaire Méditerranée Infection after their COVID-19 status was confirmed by nasopharyngeal swab testing. Informed consent was obtained from each patient. Epidemiological data were recorded, and a periodontal examination was performed by the same periodontist.
The authors also demonstrated the infectiousness of saliva from asymptomatic subjects with COVID-19. Moreover, in symptomatic patients, the presence of SARS-CoV-2 RNA in the saliva was positively associated with the loss of taste and smell  [10]. Taking into account all these data and the non-invasive nature of saliva sampling, saliva seems to be a reliable tool for detecting SARS-CoV-2  [24, 25]. Regarding dental plaque, only one study has investigated the presence of SARS-CoV-2 RNA in dental biofilms and reported that 18. 6% of symptomatic subjects whose nasopharyngeal and oropharyngeal samples tested positive harbored SARS-CoV-2 in dental plaque samples  [11]. In this study, we confirmed using RT-PCR that dental plaque samples hosted SARS-CoV-2 and we observed viral particles in dental plaque by scanning electron microscopy.
Anti-SARS-CoV-2 immunofluorescence staining on saliva sample from Participant 1 (A-C), Participant 2 (A1-C1) and Participant 3 (A2-C2). (A, A1, A2) DNA was stained using Hoechst 3342 (blue). (B, B1, B2) SARS-CoV-2 particles were stained using anti-SARS-CoV-2 antibody (orange-red), respectively. (C, C1, C2) Colocalization of Hoechst 3342 and anti-SARS-CoV-2 antibody (scale bar: 10 μm). A C K N O W L E D G E M E N T SWe thank Takashi Irie, Kyoko Imai, Shigeki Matsubara, Taku Sakazume, Toshihide Agemura, Yusuke Ominami, and the Hitachi team in Japan from Hitachi High-Tech Corporation and Hitachi Ltd. for the collaborative study conducted with IHU Méditerranée Infection, and for the installation of a SU5000 microscope at the IHU Méditerranée Infection facility. This work was supported by the French Government under the "Investissements d'avenir" programme managed by the National Agency for Research (ANR), Méditerranée-Infection 10-IAHU-03.